Overview
I am a clinical and translational investigator focused on precision therapies and biomarkers in advanced prostate and other GU cancers. I oversee a large research team of clinical and lab based investigators focused on improving patient outcomes, preventing metastatic disease, and understanding the biology of aggressive prostate cancer. Some key themes:
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. Developing prognostic and predictive models for progression and survival in metastatic prostate cancer
7. Examining surrogate markers of mortality in metastatic prostate cancer
8. Biologic basis for prostate cancer lineage plasticity, immune evasion, hormone therapy, and metastasis
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. Developing prognostic and predictive models for progression and survival in metastatic prostate cancer
7. Examining surrogate markers of mortality in metastatic prostate cancer
8. Biologic basis for prostate cancer lineage plasticity, immune evasion, hormone therapy, and metastasis
Office Hours
Mondays, Wednesdays and Fridays. Contact Cierra Strickland, my assistant at cierra.strickland@duke.edu for appointments. Or 919-668-4667.
Current Duke Appointments & Affiliations
George Barth Geller Distinguished Professor for Research in Cancer
·
2026 - Present
Medicine, Medical Oncology,
Medicine
Professor of Medicine
·
2018 - Present
Medicine, Medical Oncology,
Medicine
Professor in Urology
·
2018 - Present
Urology,
Clinical Science Departments
Professor in Pharmacology and Cancer Biology
·
2021 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Professor in Pathology
·
2026 - Present
Pathology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2006 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer.
Journal article Prostate Cancer Prostatic Dis · October 2026 BACKGROUND: In ARAMIS, darolutamide statistically significantly prolonged metastasis-free survival by 2 years and reduced the risk of death by 31% in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We report post hoc analyses of ... Full text Link to item CiteRecruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry.
Journal article Contemp Clin Trials Commun · October 2026 PURPOSE: The PROMISE Registry is a U.S. decentralized, 20-year prospective prostate cancer germline genetic registry. Here, we examine the effectiveness of different recruitment strategies, including institutional partnerships, direct-to-patient marketing ... Full text Link to item CiteExternal validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.
Journal article Cancer · October 1, 2026 BACKGROUND: Early favorable prostate-specific antigen (PSA) response to ≤0.2 ng/mL by 6 months is associated with superior overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). The nadir androgen receptor pathway inhibitor (ARPI)-d ... Full text Link to item CiteRecent Grants
Amgen Extended Dosing- AMG 509 20250211- A Phase 1b, Open-Label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2026 - 2031Defining the role of TTK in neuroendocrine prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 2031Phase 1, Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor) Alone and in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer, K36-MCRPC-001
Clinical TrialPrincipal Investigator · Awarded by K36 Therapeutics · 2026 - 2031View All Grants
Education
Johns Hopkins University ·
2008
M.Sc.
University of Virginia, School of Medicine ·
2000
M.D.
Duke University ·
1996
B.S.E.